New Protein Treatment to Fight Coronavirus
Drug Contains Interferon Beta-1A, Which Is Also Naturally Produced By the Human Body to Combat Viral Infections
Due to the newly recognized virus of COVID-19 that has wreaked havoc across the world and directly infected more than 52 million individuals in the time period of just 12 months.
Numerous scientists and researchers are currently working profoundly towards developing a viable working antidote for the coronavirus infection due to which more than 1.3 million people have died after suffering from critical stages associated with the viral pathogen.
A newly developed inhaling protein treatment to fight coronavirus has been developed that is observed to have accelerated the recovery period caused by the infection.
The latest treatment for coronavirus is expected to reduce the severity of infectious disease in patients. The Protein treatment to fight coronavirus has been developed after conducting small-scale clinical trials for the drug known as SNG001. The human trial results indicate that the users diagnosed with COVID-19 are more likely to recover from the viral pathogen, as compared to those patients who received a placebo drug.
The newly formulated drug was developed by Synairgen, a Southampton based biotechnology firm. This recently prepared protein treatment to fight coronavirus contains a naturally produced protein molecule developed by the body to combat against viral pathogens called interferon beta-1a. The SNG001, as the latest treatment for coronavirus, is inhaled into the lungs using a nebulizer to directly trigger an immunologic response from the body.
According to the team of scientist that helped in the development of the new protein treatment to fight coronavirus stated that their conclusive findings, which also have been published in a medical journal, are physical proof that this COVID-19 treatment could help in faster recovery of patients admitted in hospitals without any possible adverse side effects.
However, the research teams noted that their scientific workings require a much larger sample size compared to their previous study results, which were conducted on 98 volunteered patients.
The lead author of the control study Professor Tom Wilkinson said that the results regarding the protein treatment to fight coronavirus confirm the expectation that interferon-beta may have the potential to be used as an inhaled medicine in an attempt to restore the normal immunological response of the lungs along with an acceleration in the recovery period from COVID-19. The interferon beta is a widely used drug that has been approved globally in the injectable form for other symptoms.
Interferon-beta usage in COVID-19 antidote
The consumption of interferon-beta-1a in inhalation form provides a localized high concentration of the immunologic protein that boosts the defensive mechanism of the lungs rather than targeting and eliminating the specific viral proteins found in the lung tissue.
The protein treatment to fight coronavirus carries additional advantages of the treatment of coronavirus infection when it occurs alongside other respiratory illnesses, including respiratory syncytial virus or influenza that could commonly be encountered during the cold winter weather currently experienced across the world.
Coronavirus treatment update is regarding the SNG001 human clinical trials, including working on 48 individuals who randomly received the actual drug, while other patients received a placebo drug in the same environment. This research was double-blind, as neither the researchers nor the patients knew who received the drug and the placebo.
The research concluded that those patients in the study who received the SNG001 drug, which is an inhaling protein treatment to fight coronavirus, at least two times were likely to recover at a faster rate as compared to those who received the placebo treatment.
Although the number of patients who were enrolled in the pilot trial was very small, and the study also failed to show the impact of the treatment on mortality rate and discharge time of the patient, and even the study was not even designed to provide the latter results.